Timothy P Walbert
CIK 1349376 · Chairman, President and CEO · last filed 2026-06-22
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$2.36M
Companies
15
Total Filings
148
Lifetime Open-Market Net
-$138.96M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| KARD | Director | 20,706 | — | — | $0 | 1 | 2026-06-22 |
| MIRM | Director | 9,680 | $100.65 | $974.3K | $0 | 6 | 2026-06-17 |
| BMRN | Director | 17,686 | $63.81 | $1.13M | $0 | 3 | 2026-06-04 |
| ODTX | Director | — | $21.17 | — | $0 | 1 | 2026-05-11 |
| IPSC | Director | — | $2.00 | — | $0 | 4 | 2025-06-16 |
| SGMT | Director | — | $9.06 | — | $0 | 3 | 2025-06-10 |
| Horizon Therapeutics Public Ltd Co (HZNP) Delisted | Chairman, President and CEO | 0 | $116.30 | $0 | -$138.65M | 79 | 2023-10-06 |
| AUPH | Director | — | $15.85 | — | $0 | 2 | 2022-05-20 |
| XCUR | Director | — | $1.34 | — | $0 | 2 | 2021-06-04 |
| Assertio Holdings, Inc. (ASRT) Delisted | Director | 819 | $23.50 | $19.2K | $0 | 1 | 2020-05-22 |
| Zyla Life Sciences (EGLT) Delisted | Director | — | — | — | $0 | 5 | 2018-05-15 |
| Sucampo Pharmaceuticals, Inc. (SCMP) Delisted | Director | 0 | — | — | $0 | 4 | 2018-02-13 |
| XOMA | Director | 6,466 | $40.17 | $259.7K | $0 | 16 | 2017-05-22 |
| Raptor Pharmaceutical Corp (RPTP) Delisted | Director | 0 | — | — | -$313.5K | 9 | 2014-03-17 |
| IDM PHARMA, INC. (IDMI) Delisted | President and CEO | — | — | — | $0 | 5 | 2008-04-07 |
Recent Filings · Page 7 of 15
148 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2020-05-22 | Assertio Holdings, Inc. (ASRT) Delisted | Grant (A) | +260,254 | $0 | EDGAR |
| 2020-05-21 | — | Disp (D) | −26,953 | $0 | |
| 2020-04-28 | — | Mixed | +4,862 | $8.5K | |
| 2020-04-24 | — | Mixed | +5,715 | $10.0K | |
| 2020-03-05 | — | Grant (A) | +13,620 | $0 | |
| 2020-02-21 | Horizon Therapeutics Public Ltd Co (HZNP) Delisted | Mixed | −66,889 | -$4.08M | EDGAR |
| 2020-02-04 | Horizon Therapeutics Public Ltd Co (HZNP) Delisted | Mixed | +6,418 | -$92.0K | EDGAR |
| 2020-01-23 | Horizon Therapeutics Public Ltd Co (HZNP) Delisted | Mixed | +13,006 | -$378.6K | EDGAR |
| 2020-01-07 | Horizon Therapeutics Public Ltd Co (HZNP) Delisted | Mixed | +126,318 | -$9.10M | EDGAR |
| 2019-10-17 | Horizon Therapeutics Public Ltd Co (HZNP) Delisted | Mixed | −8,305 | -$7.16M | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.